Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press6810.17650/1994-4098-2013-0-3-4-110-113GYNECOLOGY. TREATMENTГИНЕКОЛОГИЯ. ЛЕЧЕНИЕImunotherapy opportunities in ovarian cancerВозможности иммунотерапии при раке яичниковShubinaI. Zh.ШубинаИ. Ж.
Russian Federation
GritsayA. N.ГрицайА. Н.
Russian Federation
gritsai_an@rambler.ruMamedovaL. T.МамедоваЛ. Т.
Russian Federation
SokolovN. Yu.СоколовН. Ю.
Russian Federation
KuznetsovS. A.КузнецовС. А.
Russian Federation
KiselevskiyM. V.КиселевскийМ. В.
Russian Federation
LazarevaN. I.ЛазареваН. И.
Russian Federation
KuznetsovV. V.КузнецовВ. В.
Russian Federation
TitovK. S.ТитовК. С.
Russian Federation
NikolayevA. P.НиколаевА. П.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ «РОНЦ им.Н.Н. Блохина» РАМН, МоскваAcad. N.N. Burdenko Main Military Clinical Hospital, Ministry of Defense of the Russian Federation, MoscowФГКУ «Главный военный клинический госпиталь им. акад. Н.Н. Бурденко» Минобороны России, Москва220920133-411011322072014220720142013https://ojrs.abvpress.ru/ojrs/article/view/68

In the last decade, accumulated evidence in favor of that ovarian cancer is an immunogenic tumor. Immunotherapy is aimed at stimulating the innate and adaptive immunity, may cause an effective response in patients with ovarian cancer. Various approaches immunotherapy include cytokinetherapy, use of monoclonal antibodies and cell therapy.

В последнее десятилетие накопились данные, свидетельствующие в пользу того, что рак яичников (РЯ) – это иммуногенная опухоль. Иммунотерапия, направленная на стимуляцию врожденного и адаптивного иммунитета, может вызывать эффек- тивный ответ у пациенток с РЯ. Различные подходы иммунотерапии включают цитокинотерапию, применение моноклональ- ных антител, а также клеточную терапию.

ovarian cancerantitumor immunityimmunotherapyрак яичниковпротивоопухолевый иммунитетиммунотерапия1. Siegel R., Naishadham D., Jemal A. Cancer statistics. Cancer J Clin 2012;62:10–29.Siegel R., Naishadham D., Jemal A. Cancer statistics. Cancer J Clin 2012;62:10–29.2. Cannistra S.A. Cancer of the ovary. N Engl J Med 2004;351:2519–29.Cannistra S.A. Cancer of the ovary. N Engl J Med 2004;351:2519–29.3. Chu C.S., Kim S.H., June C.H. et al. Immunotherapy opportunities in ovarian cancer. Expert RevAnticancer Ther 2008;8:243–57.Chu C.S., Kim S.H., June C.H. et al. Immunotherapy opportunities in ovarian cancer. Expert RevAnticancer Ther 2008;8:243–57.4. Zhang L., Conejo-Garcia J.R., Katsaros D. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203–13.Zhang L., Conejo-Garcia J.R., Katsaros D. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203–13.5. Clarke B., Tinker A.V., Lee C.H. et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2009;22:393–402.Clarke B., Tinker A.V., Lee C.H. et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2009;22:393–402.6. Hwang W.T., Adams S.F., Tahirovic E. et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012;124:192–8.Hwang W.T., Adams S.F., Tahirovic E. et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012;124:192–8.7. Kandalaft L.E., Powell D.J. Jr., Singh N., Coukos G. Immunotherapy for ovarian cancer: what’s next? J Clin Oncol 2011;29:925–33.Kandalaft L.E., Powell D.J. Jr., Singh N., Coukos G. Immunotherapy for ovarian cancer: what’s next? J Clin Oncol 2011;29:925–33.8. Leffers N., Fehrmann R.S., Gooden M.J. et al. Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. Br J Cancer 2010;103:685–92.Leffers N., Fehrmann R.S., Gooden M.J. et al. Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. Br J Cancer 2010;103:685–92.9. Curiel T.J., Coukos G., Zou L. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942–9.Curiel T.J., Coukos G., Zou L. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942–9.10. Sato E., Olson S.H., Ahn J. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl AcadSato E., Olson S.H., Ahn J. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl AcadSci USA 2005;102:18538–43.11. Edwards R.P., Gooding W., Lembersky B.C. et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: Twenty-four-hour versus 7-day infusion. J Clin Oncol 1997;15:3399–407.Edwards R.P., Gooding W., Lembersky B.C. et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: Twenty-four-hour versus 7-day infusion. J Clin Oncol 1997;15:3399–407.12. Vlad A.M., Budiu R.A., Lenzner D.E. et al. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 2009;59:293–301.Vlad A.M., Budiu R.A., Lenzner D.E. et al. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 2009;59:293–301.13. Hodi F.S., Butler M., Oble D.A. et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008;105:3005–10.Hodi F.S., Butler M., Oble D.A. et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008;105:3005–10.14. Hodi F.S., Mihm M.C., Soiffer R.J. et al. Biologic activity of cytotoxic T lymphocyte- associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003;100:4712–7.Hodi F.S., Mihm M.C., Soiffer R.J. et al. Biologic activity of cytotoxic T lymphocyte- associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003;100:4712–7.15. Aoki Y., Takakuwa K., Kodama S. et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 1991;51:1934–9.Aoki Y., Takakuwa K., Kodama S. et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 1991;51:1934–9.16. Fujita K., Ikarashi H., Takakuwa K. et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res 1995;1:501–7.Fujita K., Ikarashi H., Takakuwa K. et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res 1995;1:501–7.17. Hung C.F., Wu T.C., Monie A. et al. Antigenspecific immunotherapy of cervical and ovarian cancer. Immunol Rev 2008;222:43–69.Hung C.F., Wu T.C., Monie A. et al. Antigenspecific immunotherapy of cervical and ovarian cancer. Immunol Rev 2008;222:43–69.18. Odunsi K., Sabbatini P. Harnessing the immune system for ovarian cancer therapy. Am J Reprod Immunol 2008;59:62–74.Odunsi K., Sabbatini P. Harnessing the immune system for ovarian cancer therapy. Am J Reprod Immunol 2008;59:62–74.19. Sabbatini P., Odunsi K. Immunologic approaches to ovarian cancer treatment. J Clin Oncol 2007;25:2884–93.Sabbatini P., Odunsi K. Immunologic approaches to ovarian cancer treatment. J Clin Oncol 2007;25:2884–93.20. Sabbatini .P, Spriggs D., Aghajanian C. et al. Consolidation strategies in ovarian cancer: Observations for future clinical trials. Gynecol Oncol 2010;116:66–71.Sabbatini .P, Spriggs D., Aghajanian C. et al. Consolidation strategies in ovarian cancer: Observations for future clinical trials. Gynecol Oncol 2010;116:66–71.21. Reinartz S., Kohler S., Schlebusch H. et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 2004;10:1580–7.Reinartz S., Kohler S., Schlebusch H. et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 2004;10:1580–7.22. Hernando J.J., Park T.W., Kubler K. et al. Vaccination with autologous tumour antigen- pulsed dendritic cells in advanced gynaecological malignancies: Clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002;51:45–52.Hernando J.J., Park T.W., Kubler K. et al. Vaccination with autologous tumour antigen- pulsed dendritic cells in advanced gynaecological malignancies: Clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002;51:45–52.23. Liu B., Nash J., Runowicz C. et al. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 2010;3:7.Liu B., Nash J., Runowicz C. et al. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 2010;3:7.24. Wu R., Forget M.A., Chacon J. et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 2012;18(2):160–75.Wu R., Forget M.A., Chacon J. et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 2012;18(2):160–75.25. Buckanovich R.J., Facciabene A., Kim S. et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008,14:28–36.Buckanovich R.J., Facciabene A., Kim S. et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008,14:28–36.26. Блюменберг А.Г. Диссеминированные формы рака яичников (лечение и факторы прогноза). Автореф. докт. дис. М., 2002. 27. Шубина И.Ж., Блюменберг А.Г., Волков С.М. и др. Адоптивная иммунотерапия злокачественных новообразований. Вестник РАМН 2007;11:9–15.Блюменберг А.Г. Диссеминированные формы рака яичников (лечение и факторы прогноза). Автореф. докт. дис. М., 2002. 27. Шубина И.Ж., Блюменберг А.Г., Волков С.М. и др. Адоптивная иммунотерапия злокачественных новообразований. Вестник РАМН 2007;11:9–15.